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Abstract
Background: Lipoproteins are complex, globular molecules which play essential roles in the transport and
metabolism of cholesterol. Their implication in the development of cardiovascular diseases, such as atherosclerosis,
has sustained a great deal of interest in these particles. Their various functions, and their contribution to the
development of atherosclerosis, are often attributed to their protein constituents, which vary greatly among the
different lipoprotein classes. Recent advances in the field of mass spectrometry have provided insight into the array
of proteins associated with low-density lipoproteins (LDLs) and, even more so, with high-density lipoproteins
(HDLs). Plasma and serum are the most commonly used samples for the analysis of lipoproteins. Although these
lipoprotein sources are unique, it was our goal to determine whether or not their inherent differences would
ultimately affect a quantitative analysis of the LDL and HDL proteomes. To this end, we isolated LDL and HDL
fractions with fast protein liquid chromatography-size exclusion chromatography (FPLC-SEC) from both human
plasma and serum samples from the same individuals. After delipidating these samples, we performed a
quantitative proteomic analysis to compare the lipoprotein-associated proteins derived from both plasma and
serum.
Results: Although the primary differences between the samples are found in fibrinogen proteins which are
removed from serum, it of interest to note that, with respect to LDL-associated proteins, apolipoproteinB-100 was
found at significantly higher levels in serum samples. Complement component 3 was found at significantly higher
levels in serum-derived HDL fractions. Both of these proteins are known LDL- and HDL-associated proteins,
respectively.
Conclusion: Overall, the results from our study indicate that both plasma and serum samples are equally suited for
proteomic studies, and provide similar results. These findings are particularly important for studies profiling
proteomic differences in lipoprotein particle composition in a variety of disease conditions, including cardiovascular
disease.
Background
Lipoproteins, as their name implies, are complex,
globular aggregates of lipid and protein which circulate
primarily in plasma/serum, and play a central role in the
transport and metabolism of both endogenous and exo-
genous cholesterol and other lipids. It is a well estab-
lished fact that, in general, low-density lipoprotein
(LDL) levels are directly correlated with the risk for the
development of cardiovascular disease, whereas high-
density lipoprotein (HDL) levels are inversely correlated
with this risk [1,2]. The role that these particles play in
the development of atherosclerosis has sustained dec-
ades of interest in studies devoted to lipoprotein func-
tion and metabolism. As LDL and HDL are composed
of roughly twenty-two percent and fifty percent protein,
respectively, there is recognition of the fact that the pro-
tein component of these particles is largely responsible
for carrying out their various functions. Many efforts
have been focused on the elucidation of the proteomes
(the protein components) of both LDL and HDL [3-7].
Tremendous advances in the field of mass spectrometry
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teins, many of which were previously not known to
associate with lipoproteins. Since they contain a rela-
tively larger protein constituent, it is not surprising that
the majority of these lipoproteomic analyses have been
aimed at HDLs as opposed to LDLs. Nonetheless, the
identification of both LDL- and HDL-associated pro-
teins, and, in particular, the quantitative characterization
of their proteomes in disease states, provides tremen-
dous potential for the detection of risk factors and for
the development of interventions for the treatment of
lipoprotein-associated disorders.
The proteomic studies which have concentrated on
HDL have collectively identified over eighty different
proteins [3,5-7]. Several of these proteins and enzymes,
which likely mediate the atheroprotective functions of
HDL, have been found to be altered in cardiovascular
and metabolic diseases. A recent shotgun proteomics
analysis of HDL has revealed that these particles contain
not only proteins involved in lipid metabolism, but also
proteins that are involved in complement regulation,
inflammation and proteinase inhibition [7]. Vaisar et al.
also characterized the HDL3 subset of patients with
established coronary artery disease and found it to be
selectively enriched in inflammatory response and com-
plement pathway proteins such as paraoxonase-1
(PON1) and complement component 3 (C3). Activity
levels of PON-1, a low-abundance HDL-associated pro-
tein, have been found to be decreased in patients with
metabolic syndrome [8]. Furthermore, there is evidence
that a number of other low-abundance proteins, which
may only weakly associate with HDL particles, are
altered in potentially proatherogenic conditions. Under
inflammatory conditions, it has been shown that both
apolipoprotein J (clusterin) and serum amyloid A (SAA)
levels increase [9-11].
One of the goals of the HUPO Plasma Proteome Pro-
ject (PPP), which was piloted in 2002, is to analyze com-
prehensively the protein constituents of human plasma
and serum [12]. As a result of this initiative, several of
the challenges associated with studying plasma, serum,
and their constituents, such as lipoproteins, have been
highlighted. One such challenge is related to the fact
that plasma and serum are highly complex samples for
proteomic analyses. The dynamic range of proteins
found in plasma and serum spans greater than ten
orders of magnitude, exceeding even the most sensitive
mass spectrometers [13], thereby making the detection
of proteins on the low-abundance end of the spectrum
more difficult. With this knowledge, several methods for
the depletion of the most abundant plasma proteins
have been developed. With respect to the analysis of
lipoproteins, arguments have been made for the selective
enrichment of lipoprotein-specific proteins such as
apolipoprotein B-100 (apoB-100) and apolipoprotein A-I
(apoA-I) via immunoaffinity chromatography. However,
the major concern over the employment of such deple-
tion techniques is related to the loss of potential pro-
teins of interest associated with lipoproteins as we have
previously described [14]. Nonetheless, the issue of sen-
sitivity is a concern which can be extended to the field
of lipoproteomics.
Plasma and serum, which are very similar in protein
composition, are the most commonly used samples for
the analysis of lipoproteins. Although serum contains
less protein (due to removal of the fibrin clot), the
products of in vitro proteolysis, which occurs during
the clotting process, may alter the protein composition
of the serum sample [15]. Consequently, much of the
argument favoring the use of plasma over serum in
proteomic studies stems from the concern over in
vitro proteolysis. Although we recognize that plasma
and serum are qualitatively unique, it was our goal to
determine if their inherent differences affect the quan-
titative analysis of LDL- and HDL-associated proteins.
Given the difficulties in analyzing samples with broadly
ranging protein abundances, it will be beneficial to
select a sample which will yield the best results with
respect to identifying lipoprotein-associated proteins.
Following the same reasoning, it would be equally ben-
eficial to know that, if there are no significant differ-
ences between the abundances of lipoprotein-
associated proteins in serum and plasma, the use of
one sample over the other will not substantially bias
one’s results and conclusions. To this end, we isolated
LDL and HDL from plasma and serum collected from
healthy volunteers using fast protein liquid chromato-
graphy-size exclusion chromatography (FPLC-SEC).
After delipidating these samples, we quantified the
lipoprotein-associated proteins in plasma and serum.
Our results show that the primary differences between
the samples are found in the fibrinogen proteins found
in plasma which are contained within the fibrin clot
and are removed from serum. Therefore, plasma and
serum are of equal value for quantitative analyses of
either the LDL or HDL proteomes.
Results
It was the purpose of the present study to determine if
there are significant differences between plasma and
serum with respect to the proteins identified in the
FPLC-SEC-derived lipoprotein fractions. In particular,
our goal was to analyze the FPLC-SEC-derived fractions
containing LDL and HDL particles. After isolating the
lipoprotein particles and performing lipid extractions,
the protein constituents of LDL and HDL were analyzed
by nano-HPLC electrospray ionization tandem mass
spectrometry. We identified proteins unique to the LDL
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found in Tables 1 and 2, respectively. We also compiled
a list of proteins which overlap between the two lipo-
protein fractions. This list can be found in Table 3.
A representative total ion chromatogram for one of the
FPLC-derived plasma HDL fractions along with a
selected mass spectrum for an identified peptide can be
found in Additional File 1.
Analysis of LDL fraction
All of the proteins meeting the criteria for inclusion in
the analysis of LDL fractions, along with the average
scan counts for each protein, can be found in Addi-
tional File 2. Excluded from this list are two proteins
which were identified as redundant proteins: pregnancy
zone protein (PZP_HUMAN) and hemoglobin delta
subunit (HBD_HUMAN). Among the proteins which
were found to have significantly higher average scan
counts in LDL particles derived from plasma are fibri-
nogens (alpha, beta and gamma chains), and hemoglo-
bin subunits alpha and beta. Those proteins with
significantly higher average scan counts found in the
LDL fractions derived from serum include alpha-2-
macroglobulin, apolipoprotein B-100, C4b-binding pro-
tein alpha chain, fibronectin, haptoglobin, haptoglobin-
related protein and prothrombin. In total, 16 proteins
were found in only the LDL fraction, and these pro-
teins are listed in Table 1. Hemoglobin subunits alpha
and beta are the proteins with significantly higher
average scan counts in plasma, and none of the LDL-
unique proteins exhibit significantly higher average
scan counts in serum.
Analysis of HDL fraction
All of the proteins meeting the criteria for inclusion in
the analysis of the HDL fraction, along with the average
scan counts for each protein, can be found in Additional
File 3. Excluded from this list are two proteins which
were identified as redundant proteins: pregnancy zone
protein (PZP_HUMAN) and complement factor H
related protein 1 (FHR1_HUMAN). Fibrinogen beta
chain is the only protein that was found to have a signif-
icantly higher average scan count in plasma, while com-
plement component 3 and alpha-2-macroblobulin are
the proteins with significantly higher average scan
counts in serum. Among the proteins unique to the
HDL fraction, the only protein found with a significant
difference between plasma and serum is complement
component 3. A total of 65 proteins were identified to
be unique to HDL, and these proteins are listed in
Table 2.
Discussion
The goal of the present study was to compare the utility
of plasma and serum samples for shotgun lipoproteomic
analyses. Over the past few years, a great deal of interest
has been directed toward the elucidation of the proteins
associated particularly with HDL particles as these parti-
cles have been found to contain a diverse protein consti-
tuent [3,5-7]. As alterations in particular proteins
associated with HDLs have been identified in several
disease states, there the potential for the discovery and
detection of quantitative alterations in these proteins as
indicators of early risk factors for cardiovascular disease.
Advances in mass spectrometry have allowed for the
Table 1 Proteins unique to the LDL fraction
Protein Accession Protein Description Plasma Avg. Scan Count ± SEM Serum Avg. Scan Count ± SEM
P02745 Complement C1q subcomponent subunit A 1 ± 0.63 1.2 ± 0.63
P02746 Complement C1q subcomponent subunit B 1 ± 0.52 2.2 ± 0.95
P02747 Complement C1q subcomponent subunit C 1.7 ± 0.47 3 ± 1.3
P00736 Complement C1r subcomponent 5.7 ± 1.7 3.2 ± 2.6
P09871 Complement C1 s subcomponent 0.33 ± 0.30 0.8 ± 0.48
P20851 C4b-binding protein beta chain 0.67 ± 0.47 1.4 ± 1.2
O43866 CD5 antigen-like 8.3 ± 2.8 12.8 ± 4.2
P00488 Coagulation factor XIII A chain 0.33 ± 0.30 0
O75636 Ficolin-3 0.17 ± 0.24 1.2 ± 0.48
P07359 Platelet glycoprotein Ib alpha chain 0.17 ± 0.24 0.4 ± 0.5
P69905 Hemoglobin subunit alpha 18.2 ± 25 * 1.8 ± 1.4
P68871 Hemoglobin subunit beta 34.5 ± 48 * 5.6 ± 3
Q08380 Galectin-3-binding protein 2.3 ± 1.3 2.2 ± 1.3
Q93074 Mediator of RNA polymerase II transcription subunit 12 0.33 ± 0.47 2.6 ± 1.9
P27918 Properdin 0 0.8 ± 0.6
P07225 Vitamin K-dependent protein S 2.8 ± 1.9 3.4 ± 3.5
The average scan count ± SEM is provided for each protein identified in only the LDL fraction derived from both plasma and serum. (P < 0.001; * significantly
greater in plasma;† significantly greater in serum)
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Protein Accession Protein Description Plasma Avg. Scan Count ± SEM Serum Avg. Scan Count ± SEM
P02763 Alpha-1-acid glycoprotein 1 7.3 ± 6.5 5.1 ± 4.7
P19652 Alpha-1-acid glycoprotein 2 2 ± 1.3 0.67 ± 0.41
P04217 Alpha- 1B-glycoprotein 5.1 ± 3.9 5.2 ± 4.3
P08697 Alpha-2-antiplasmin 2.6 ± 1.7 2.6 ± 1.9
P02750 Leucine-rich alpha-2-glycoprotein 0.89 ± 0.79 0.89 ± 1.2
P01011 Alpha-1-antichymotrypsin 6.9 ± 5.4 6.2 ± 6.7
P43652 Afamin 1.8 ± 1.3 1.7 ± 1.4
P35858 Insulin-like growth factor-binding protein 2.4 ±1 1.9 ± 1.2
P01019 Angiotensinogen 2.6 ± 1.9 1 ± 1.6
P01008 Antithrombin-III 5.2 ± 4.6 3.8 ± 4.2
P06727 Apolipoprotein A-IV 2.9 ± 2.8 3.4 ± 3.4
P02654 Apolipoprotein C-I 0.67 ± 0.41 1.4 ± 0.65
P02655 Apolipoprotein C-II 0.22 ± 0.25 0.44 ± 0.42
P05090 Apolipoprotein D 0.67 ± 0.5 0.44 ± 0.42
P02749 Apolipoprotein H 4.9 ±4 4.8 ± 3.8
O95445 Apolipoprotein M 0.89 ± 0.45 0.67 ± 0.5
O75882 Attractin 0.22 ± 0.25 0
P43251 Biotinidase 0.11 ± 0.19 0.22 ± 0.25
P08185 Corticosteroid-binding globulin 1 ± 0.9 0.78 ± 1
P00450 Ceruloplasmin 23.6 ± 7.6 23.1 ± 11.6
P00751 Complement factor B 4.4 ± 2.8 4.1 ± 3.3
P05156 Complement factor I 1 ± 0.9 1 ± 1.3
P06681 Complement C2 1.1 ± 0.67 0.67 ± 0.76
P01024 Complement C3 116 ± 43 139.6 ± 64 t
P01031 Complement C5 4.9 ± 2.7 4.1 ± 2.3
P13671 Complement component C6 3.3 ± 1.3 2.9 ± 1.6
P10643 Complement component C7 1.3 ± 0.87 1.6 ± 1.2
P07357 Complement component C8 alpha chain 0.22 ± 0.25 1 ± 0.87
P07358 Complement component C8 beta chain 1.2 ± 0.75 0.78 ± 0.81
P07360 Complement component C8 gamma chain 0.78 ± 0.48 0.78 ± 0.48
P02748 Complement component C9 0.78 ± 0.81 1.4 ± 1.5
P22792 Carboxypeptidase N subunit 2 0.56 ± 0.51 0.78 ± 0.56
Q16610 Extracellular matrix protein 1 0.44 ± 0.42 0.11 ± 0.19
P00748 Coagulation factor XII 1.2 ± 1.3 1.3 ± 1.1
P02765 Alpha-2-HS-glycoprotein 7.4 ± 6 6.1 ± 5.8
Q03591 Complement factor H-related protein 1 0.78 ± 0.63 0.56 ± 0.58
P06396 Gelsolin 3.6 ± 3.3 3.7 ± 4.6
P02790 Hemopexin 12.4 ± 9.9 12.9 ± 10.7
P05546 Heparin cofactor 2 1.2 ±1.3 1 ± 1
P04196 Histidine-rich glycoprotein 2.9 ±1.8 1.3 ± 1
P05155 Plasma protease C1 inhibitor 4.9 ± 2.5 4.6 ± 2.9
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 7.4 ± 5.1 8.4 ± 5
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 1.1 ± 0.45 0.56 ± 0.42
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 16 ± 3.8 17.9 ± 9.8
P03952 Plasma kallikrein 1 ± 0.58 1.1 ± 0.67
P01042 Kininogen-1 5.3 ± 1.2 4.4 ± 2
P51884 Lumican 2 ± 0.65 2.4 ± 1.3
Q9NU22 Midasin 0.11 ± 0.19 0.11 ± 0.19
P36955 Pigment epithelium-derived factor 1 ±0.87 0.68 ± 1.2
Q96PD5 N-acetylmuramoyl-L-alanine amidase 1.4 ± 1.1 1.6 ± 1.5
P00747 Plasminogen 4.7 ± 5.1 6 ± 6.3
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tures [16,17]. Since the quantitative aspect of such analyses
provides great potential, it would be advantageous to select
a sample which will yield optimal, unbiased results. To this
end, as plasma and serum are the most commonly used
samples for lipoprotein analyses, it was our objective to
determine if the use of one sample type over the other
would significantly affect the relative abundance of pro-
teins. Furthermore, although proteomic analyses have
been performed on LDL particles [4], we have not
uncovered any shotgun proteomic studies on this lipopro-
tein class. To our knowledge, this is the first report of a
shotgun proteomic analysis of the LDL fraction.
We identified approximately 65% of the proteins
previously reported as LDL-associated proteins [4,18]. In
our analysis, all of these confirmed LDL-associated pro-
teins (alpha-1-antitrypsin, alpha-2-macroglobulin, serum
albumin, apolipoproteins A-I, B-100, C-III, E, and
J, fibrinogen, fibronectin and haptoglobin) were also iden-
tified in the HDL fraction (Table 2). In comparing our
Table 2 Proteins unique to the HDL fraction (Continued)
P02753 Retinol-binding protein 4 0.33 ± 0.29 0.44 ± 0.59
P35542 Serum amyloid A-4 protein 0.33 ± 0.5 0.22 ± 0.38
P02743 Serum amyloid P-component 2.4 ± 1.3 2.6 ± 1.4
P49908 Selenoprotein P 0.11 ± 0.19 0.22 ± 0.25
P04278 Sex hormone-binding globulin 0.22 ± 0.25 0.78 ± 0.9
Q8WYL5 Protein phosphatase Slingshot homolog 1 0.44 ± 0.42 0.11 ± 0.19
The average scan count ± SEM is provided for each protein identified in only the HDL fraction derived from both plasma and serum. (P < 0.001; * significantly
greater in plasma; † significantly greater in serum)
Table 3 Proteins found in both the LDL fraction and the HDL fraction
LDL Fractions HDL Fractions
Protein Description Plasma Avg. Scan
Count ± SEM
Serum Avg. Scan
Count ± SEM
Plasma Avg. Scan
Count ± SEM
Serum Avg. Scan
Count ± SEM
Alpha-1 -antitrypsin 2 ± 0.97 0.4 ± 0.52 39.8 ± 33.3 41 ± 43.8
Alpha-2-macroglobulin 475 ± 166 753 ± 171 11.1 ± 7.7 37.6 ± 38†
Serum Albumin 5.8 ± 5 7 ± 5.4 324.5 ± 243.4 306.1 ± 221.1
Alpha-1-microglobulin 0 0.4 ± 0.9 2.3 ± 1.1 2.3 ± 1.1
Apolipoprotein A-I 9 ± 2.2 11 ± 2.3 123.1 ± 30 107.2 ± 42
Apolipoprotein A-II 2.5 ± 1 3.2 ± 1 24.2 ± 6.5 26.7 ± 11.1
Apolipoprotein B-100 98 ± 19 167 ± 94† 0.44 ± 0.42 0.56 ± 0.30
Apolipoprotein C-III 5.7 ± 3.4 11.2 ± 8.8 1.9 ± 0.61 1.7 ± 0.58
Apolipoprotein E 4.8 ± 2.5 7.4 ± 2.7 1.8 ± 0.81 1.2 ± 1
Apolipoprotein-L1 2.3 ± 0.94 3 ± 1 0.78 ± 0.38 0.33 ± 0.29
Complement C1 s subcomponent 0.33 ± 0.3 0.8 ± 0.48 0.56 ± 0.3 0.78 ± 0.75
C4b-binding protein 17.5 ± 6.1 36 ± 28† 0 0.33 ± 0.41
Complement factor H 3. 5 ± 2.9 6.8 ± 6.1 5.7 ± 5.4 6.6 ± 4.7
Apolipoprotein J (Clusterin) 2.3 ± 0.79 2.8 ± 2.1 2.6 ± 0.65 2.9 ± 1.3
Complement C4-A 1.7 ± 1 0.2 ± 0.25 38.8 ± 14.7 34.2 ± 16
Coagulation factor XIII B chain 0.67 ± 0.47 0 0 0.44 ± 0.42
Fibrinogen alpha chain 133.7 ± 35.3 * 0 1.1 ± 1.1 0
Fibrinogen beta chain 149.2 ± 21 * 0 2 ± 1.7 * 0
Fibrinogen gamma chain 143 ± 28 * 0 0.78 ± 0.9 0
Fibronectin 57.2 ± 24 98.8 ± 38† 0.89 ± 0.79 0.44 ± 0.58
Haptoglobin 5.5 ± 4 19.2 ± 15.3† 11.3 ± 9.3 7 ± 4.1
Haptoglobin-related protein 19 ± 14 47.6 ± 33† 40.1 ± 28.8 29.4 ± 18
Inter-alpha-trypsin inhibitor heavy chain H2 0.5 ± 0.48 1.8 ± 1.25 7.6 ± 4.4 10.3 ± 6.8
Paraoxonase-1 0.5 ± 0.32 0.8 ± 1 2.7 ± 0.96 2.9 ± 1.1
Prothrombin 0 10.4 ± 2.1† 6.6 ± 4 4 ± 2.8
Vitronectin 0.5 ± 0.3 1.8 ± 1.1 4.1 ± 2.6 3.4 ± 1.7
The average scan count ± SEM is provided for each protein identified in both the LDL and HDL fractions derived from plasma and serum. (P < 0.001; *
significantly greater in plasma; †significantly greater in serum)
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tein analyses [3-7,18], this overlap between LDL- and
HDL-associated proteins has been confirmed for all but
one protein identified in our LDL fraction, fibronectin
[which has previously been shown only to associate with
LDL [4]].
With respect to the HDL fraction, we identified 65
total proteins unique to the HDL fraction. Of these 65
proteins, 15 (alpha-1-acid glycoprotein 1, alpha-1B-gly-
coprotein, alpha-2-antiplasmin, alpha-2-HS-glycoprotein,
angiotensinogen, apolipoproteins C-I, D, and H, comple-
ment C3, complement C9, inter-alpha-trypsin inhibitor
heavy chain H4, kininogen-1, retinol-binding protein 4,
serotransferrin and transthyretin) were confirmed to be
HDL-specific by other studies [3,5-7]. Four of the pro-
teins listed in Table 2 (apolipoproteins A-IV, C-II and
M, and serum amyloid A-4) were found by others to be
associated with both HDL and LDL [3,5-7,18,19]. Taken
together, these results indicate that there is still work to
be done in order to conclusively state which proteins
are associated uniquely with either LDL or HDL parti-
cles. If these lipoprotein particles do indeed share speci-
fic proteins, it will be of great interest to determine if
these particles exchange certain proteins in the course
of their normal biological function.
Regarding the differences between LDL particles and
HDL particles derived from plasma and serum, our
results indicate that the primary differences between the
samples are found in the fibrinogen proteins which are
contained within the fibrin clot and are removed from
serum. Therefore, it is not surprising that the majority
of the proteins exhibiting significantly higher scan
counts in plasma are the fibrinogen proteins. With
respect to LDL-associated proteins, it is of interest to
note that apoB-100 was found at significantly higher
levels in serum samples. This may suggest that if it is
one’s goal to analyze apoB-100, specifically, perhaps
serum would be the preferred sample choice.
In addition to our findings related to the quantitative
differences between LDL- and HDL-associated proteins
derived from plasma and serum, the results from our
shotgun proteomic analysis of LDL provide insights into
the protein cargo associated with these particles. All of
the proteins listed in Table 1, which we have deter-
mined to be unique to the LDL fraction derived from
our FPLC isolation, have never been reported as LDL-
associated proteins. These findings suggest that we have
identified several potentially novel, LDL-associated pro-
teins. However, given the fact that the majority of these
proteins are found at relatively low levels, future studies
are warranted in order to confirm their association.
Nonetheless, proteins such as galectin-3-binding protein
and several complement subcomponents may provide
insight into the biological function of LDL. It has been
reported that HDL particles are enriched in several
complement proteins, suggesting that HDLs play a role
in complement pathway activation [7]. As we were able
to identify several different complement subcomponents
in the LDL fraction, this may suggest that LDL particles
also play a role in complement pathway activation. Of
other potential interest is galectin-3-binding protein,
which has been shown to promote integrin-associated
cell adhesion [20,21]. Given the critical role of cell adhe-
sion contributing to plaque formation in atherosclerosis
and the central role that LDL particles play in the pro-
gression of this disease, a protein such as galectin-3-
binding protein may serve as the basis for future studies
regarding its possible etiological implication.
A concern with studies such as this is with the purity
of the lipoprotein isolations and whether or not certain
identified proteins are truly lipoprotein-associated, or
are contaminants from either plasma or serum which
happen to co-elute with either LDL or HDL particles in
the FPLC-SEC fractionation. Our study may suggest
that an identification of a particular protein in either
LDL or HDL fractions derived from both serum and
plasma samples bolsters the argument that it is indeed
associated with a lipoprotein particle and not merely a
contaminant from either plasma or serum. For example,
if certain proteins, such as the fibrinogen proteins, were
found at significantly higher levels in just plasma- or
serum-derived lipoprotein fractions, it would suggest
that those proteins are likely contaminants and may not
in fact be associated with a lipoprotein particle. Overall,
our data suggests that a successful quantitative analysis
of either the LDL or HDL proteomes can be accom-
plished with either plasma or serum samples.
Methods
Plasma and Serum Samples
The protocol for the acquisition of blood samples from
volunteers was approved by an Institutional Review
B o a r da tt h eM e d i c a lC o l l e g eo fW i s c o n s i n .W r i t t e n
consents were obtained from each volunteer prior to
inclusion in this study. Plasma and serum samples were
obtained from three random, healthy donors. No identi-
fying health information was collected. For the methods
described below, for both the plasma and serum sam-
ples, a total of three biological replicates were analyzed.
Materials
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise noted.
Isolation of plasma lipoproteins by FPLC-SEC
FPLC-size exclusion chromatography (FPLC-SEC) analysis
was carried out on a BioLogic DuoFow QuadTec 10 Sys-
tem equipped with a BioFrac fraction collector (Bio-Rad
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Briefly, a single Superdex 200 10/300 GL column (GE
Healthcare, Uppsala, Sweden) was used for the size-exclu-
sion chromatography. Elutions were performed in a 1 mM
EDTA, 150 mM NaCl, 0.02% NaN3 phosphate buffered
saline solution, pH 7.4. Prior to each sample injection into
the FPLC-SEC system, 12 mL of eluent buffer, run at 0.3
mL/min, was used to ensure equilibration of the column.
Plasma and serum sample aliquots of 200 μLw e r eu s e d
for each injection. The elutions were carried out at a flow
rate of 0.30 mL/min with a maximum pressure of 218 psi.
Fractions of 0.5 mL were collected in pre-treated polypro-
pylene tubes throughout the analysis. Fractions corre-
sponding to discrete elution peaks and/or troughs were
pooled as previously described [14] and then concentrated
using pre-blocked Vivaspin 500 spin columns
(Vivascience, Hannover, Germany). After pooling the 0.5
mL fractions together based on their correspondence with
either a discrete elution peak or trough, a total of eight dif-
ferent fraction sets is formed. Fraction sets 2-4, which
elute between approximately 20 and 23.5 mL, corresponds
to the LDL fraction. These volumes take into account the
12 mL used for column equilibration. Fraction sets 4-7,
which elute between approximately 23.5 and 28 mL, con-
tain the HDL fraction. Extensive studies were previously
performed by our group in order to validate the location
of both LDL and HDL within these elution volumes [14].
As indicated, there is a potential overlap between the LDL
and HDL fraction sets in fraction set four. In order to
avoid potential contamination and crossover between the
LDL and HDL proteomic analysis, fraction set four, which
elutes between 23.5 and 24.5 mL, was not included.
Chloroform extractions and sample preparation for mass
spectral analysis
The concentrated FPLC-SEC plasma and serum fraction
sets were delipidated via a series of chloroform extrac-
tions [protocol adapted from Mirza et al.[ 2 2 ]a n dp r e -
viously described by Collins et al. [14]]. Following the
delipidation procedure, the proteins were reduced with
10 mM dithiothreitol (DTT) at 37°C for 30 min and
subsequently alkylated with 55 mM iodoacetamide [23]
at 37°C for 45 min in dark. The proteins were then
digested with trypsin (Promega, Madison, WI) at a ratio
of 1:50 trypsin to protein for 12 h at 37°C. Digestions
were quenched with the addition of 1 μLo f1 0 %f o r m i c
acid. The samples were then cleaned with C18 Zip-Tips
(Millipore, Billerica, MA) prior to mass spectral analysis.
Nano-HPLC-electrospray ionization tandem mass
spectrometry
The protein digests from both plasma and serum lipo-
protein fractions were analyzed on a ThermoFinnigan
LTQ ion trap mass spectrometer interfaced with a
nano-LC system (Thermo Electron) equipped with an
autosampler through which samples were loaded onto a
C18 capillary column (100 × 0.1 mm). The capillary col-
umn was packed in-house with 5 μmC 18 RP particles
(Phenomenex, Cheshire, UK). The solvents A and B,
used for the chromatographic separation of peptides,
were 5% acetonitrile in 0.1% formic acid and 95% aceto-
nitrile in 0.1% formic acid, respectively. The protein
digest injected onto the microcapillary column was
resolved at a rate of 150 μL/min, by the following gradi-
ent conditions: 0-120 min 0-25% B, 120-180 min 25-
75% B, 180-190 min 75-100% B, 190-200 min 100% B,
215-300 min 100% A.
Protein identification and data analysis
Peak lists were generated from raw LC-MS/MS spectra
using ExtractMS v. 3. The raw data acquired by the
mass spectrometry experiment were searched against
the human UniProt database (Uniprot v. 49.1, which
contains 13,488 proteins and 7,360,189 amino acids)
using the SEQUEST [24] (TurboSEQUEST v. 27 rev. 12)
search engine. Additional search parameters included a
precursor-ion mass tolerance of ±2.5, and a fragment-
ion mass tolerance of 0. The output files from the data-
base search were filtered and summarized using the pro-
gram Epitomize [25]. The filter allows for a positive
peptide, and hence protein, identification based on Pro-
tein Probability scores. The algorithm which generates
the Protein Probability scores utilizes decoy database
searching and is a modified version of the Peptide Pro-
phet [19] algorithm. The Protein Probability scores are
calculated with a modified version of the algorithm,
Peptide Prophet.
Visualize http://proteomics.mcw.edu/visualize, a bioin-
formatics tool which allows for visualization and analysis
of data produced by Epitomize, allows for the combina-
tion and comparison of the data obtained from each of
the plasma and serum sample runs for each fraction set.
Visualize allows the user to manually set the criteria for
filtering data. The criteria for the positive identification
of a protein, in this case, were set at a protein probabil-
ity of 0.85 and a requirement for the identification of at
least two unique peptides. These criteria are equivalent
t oag l o b a lf a l s ed i s c o v e r yr a t eo ff i v ep e r c e n t .D u et o
their ubiquitous presence in both plasma and serum,
and lack of evidence that they contribute meaningfully
to lipoprotein function, immunoglobulins were not ana-
lyzed. Keratin proteins were also removed from the data
set as they are common contaminants of such experi-
ments. In order to address the issue of protein name
redundancy, we not only searched our mass spectrome-
try data against a non-redundant protein database, Uni-
Prot, but we also utilized a function in Visualize which
allows for the assessment of protein redundancy. Using
Collins and Olivier Proteome Science 2010, 8:42
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Page 7 of 9this feature of Visualize, we performed a removal of any
redundant proteins at the peptide level. An average scan
count and standard error of the mean was calculated for
each protein derived both from plasma and from serum
for both the LDL and HDL fractions. P values were cal-
culated for each protein and then corrected by a Bonfer-
roni adjustment procedure. These calculations allow us
to compare and contrast the protein population asso-
ciated with LDLs and HDLs derived from plasma and
serum.
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